All Oncology News

Elotuzumab plus PVd elicited responses in patients with relapsed/refractory multiple myeloma after a median of 3 prior lines of therapy.

Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib.

Updated NCCN Guidelines recommend pemivibart in immunocompromised patients with B-cell lymphomas who are at higher risk of contracting COVID-19.

Nivolumab has been approved for subcutaneous use across several adult solid tumor indications that have an existing indication for intravenous use.

Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.

Nataliya Uboha, MD, PhD, underscores the crucial role of molecular profiling for guiding first-line treatment approaches in esophageal adenocarcinoma.

Findings from a matching-adjusted indirect comparison showed a PFS benefit with zanubrutinib vs orelabrutinib in relapsed/refractory mantle cell lymphoma.

Vivek Patel, MD, discusses the evolving roles of chemoimmunotherapy and bispecific antibodies in the first-line follicular lymphoma setting.

Asciminib plus nilotinib, imatinib, or dasatinib were effective in patients with CML in chronic or accelerated phase.

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

The EMA’s CHMP recommended the EU approval of first-line tislelizumab plus chemotherapy for adults with recurrent or metastatic nasopharyngeal carcinoma.

Eftilagimod alfa plus radiotherapy and pembrolizumab improved tumor hyalinization/fibrosis rates vs radiotherapy alone in resectable soft tissue sarcoma.

CHMP backed perioperative durvalumab plus neoadjuvant chemotherapy for MIBC based on the NIAGARA trial, which showed improved EFS vs chemotherapy alone.

David S. Hong, MD, discusses the full FDA approval of larotrectinib for NTRK fusion–positive solid tumors.

Elena Maroto-Martin, PhD, highlights the mechanism of action and efficacy of MZB1 TCR-like CAR T-cell therapy in multiple myeloma.

Vincent Ma, MD, emphasizes the need for novel therapies for patients with melanoma who are refractory to or ineligible for standard checkpoint inhibition.

SVR10 at week 12 was associated with favorable OS among patients with myelofibrosis and thrombocytopenia treated with pacritinib in the PERSIST-2 trial.

In a study recently published by researchers at Fox Chase Cancer Center, patients being treated for retroperitoneal sarcoma at multiple facilities experienced longer delays between diagnosis and treatment.

Talquetamab plus teclistamab produced responses with a high rate of infections in relapsed/refractory multiple myeloma.

Zanubrutinib showed high response rates and durable responses among Japanese patients with CLL/SLL and Waldenström macroglobulinemia.

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

Momelotinib was associated with anemia benefits and reduced transfusion burden in myelofibrosis in a post hoc analysis of 4 trials.

Alana Welm, PhD, is now the chair of the Department of Oncological Sciences in the Spencer Fox Eccles School of Medicine at the University of Utah.

The EMA’s CHMP has recommended the approval of inavolisib plus palbociclib/fulvestrant in PIK3CA-mutated, ER-positive advanced breast cancer.

The EMA’s CHMP has recommended the approval of obecabtagene autoleucel for adult patients with relapsed/refractory B-ALL.

Two-year follow-up data continued to show an overall survival benefit with glofitamab plus chemotherapy in relapsed/refractory DLBCL.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of belantamab mafodotin (Blenrep) in adult patients with relapsed or refractory multiple myeloma.

The EMA’s CHMP has issued a positive opinion for mirdametinib for pediatric and adult patients with NF1-associated plexiform neurofibromas.

Seema A. Bhat, MD, discusses the current treatment landscape of chronic lymphocytic leukemia in light of the FDA approvals of liso-cel and pirtobrutinib.